Brief: G1 Therapeutics And Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement For Lerociclib For Radioprotective Uses
22/05/2024 12:37
G1 Therapeutics Inc GTHX.O :
* G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL
(EXCLUDING ASIA-PACIFIC) LICENSE AGREEMENT FOR LEROCICLIB FOR
RADIOPROTECTIVE USES
* G1 THERAPEUTICS- SEES TO GET SHARES OF DEIMOS COMMON STOCK
REPRESENTING 10% OF DEIMOS' OUTSTANDING EQUITY CAPITALIZATION ON
A FULLY DILUTED BASIS
* G1 THERAPEUTICS INC - TO GET A 20% ROYALTY ON AGGREGATE
ANNUAL
NET SALES OF LEROCICLIB
Source text for Eikon: ID:nGNX2VP6Pc
Further company coverage: GTHX.O
Recent news on G1 Therapeutics
See all newsG1 Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon
U.S. STOCKS ON THE MOVE-Ralph Lauren, Illumina, Disney
U.S. STOCKS ON THE MOVE-Walt Disney, SpringWorks, Shopify